Kyung Dong Pharmaceutical Co., Ltd. (KOSDAQ:011040)
South Korea · Delayed Price · Currency is KRW 5,640.00
-10.00 (-0.18%)
At close: Apr 21, 2026
Kyung Dong Pharmaceutical Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 196,273 | 193,936 | 162,674 | 182,718 | 177,611 |
Other Revenue | -0 | -0 | - | -0 | - |
| 196,273 | 193,936 | 162,674 | 182,718 | 177,611 | |
Revenue Growth (YoY) | 1.21% | 19.22% | -10.97% | 2.88% | 2.18% |
Cost of Revenue | 79,172 | 79,571 | 73,331 | 86,808 | 79,528 |
Gross Profit | 117,101 | 114,365 | 89,344 | 95,910 | 98,082 |
Selling, General & Admin | 99,917 | 98,621 | 86,471 | 70,602 | 68,447 |
Research & Development | 7,793 | 11,120 | 13,827 | 12,618 | 10,537 |
Amortization of Goodwill & Intangibles | 326.24 | 341.93 | 52.23 | 2.7 | 6.99 |
Other Operating Expenses | 531.12 | 599.24 | 12,469 | 2,434 | 1,603 |
Operating Expenses | 109,435 | 111,741 | 114,298 | 87,598 | 82,324 |
Operating Income | 7,666 | 2,624 | -24,955 | 8,312 | 15,758 |
Interest Expense | -1,775 | -2,159 | -1,596 | -867.87 | -65.82 |
Interest & Investment Income | 2,687 | 2,518 | 3,170 | 2,702 | 2,610 |
Earnings From Equity Investments | -66.38 | 503.27 | 3,083 | 11,387 | -155.57 |
Currency Exchange Gain (Loss) | 11.7 | 266.84 | -5.73 | -40.15 | 161.08 |
Other Non Operating Income (Expenses) | -745.79 | -192.72 | -410.62 | -1,701 | -736.18 |
EBT Excluding Unusual Items | 7,778 | 3,561 | -20,714 | 19,792 | 17,572 |
Gain (Loss) on Sale of Investments | -748.83 | 1,765 | 2,149 | -1,709 | 786.97 |
Gain (Loss) on Sale of Assets | 2,094 | 92.39 | 61.03 | -142.27 | 73.23 |
Asset Writedown | - | -197.41 | - | - | - |
Pretax Income | 9,123 | 5,221 | -18,503 | 17,941 | 18,432 |
Income Tax Expense | 672.05 | -226.72 | 2,227 | 5,828 | 5,806 |
Earnings From Continuing Operations | 8,451 | 5,448 | -20,730 | 12,113 | 12,627 |
Minority Interest in Earnings | 77.9 | 21.86 | 22.77 | 48.4 | 45.13 |
Net Income | 8,529 | 5,470 | -20,708 | 12,161 | 12,672 |
Net Income to Common | 8,529 | 5,470 | -20,708 | 12,161 | 12,672 |
Net Income Growth | 55.93% | - | - | -4.03% | 1.71% |
Shares Outstanding (Basic) | 27 | 27 | 27 | 27 | 28 |
Shares Outstanding (Diluted) | 27 | 27 | 27 | 27 | 28 |
Shares Change (YoY) | 0.49% | -0.70% | -0.27% | -1.14% | 12.18% |
EPS (Basic) | 316.00 | 203.00 | -763.17 | 446.96 | 460.42 |
EPS (Diluted) | 315.00 | 203.00 | -763.17 | 446.96 | 460.42 |
EPS Growth | 55.17% | - | - | -2.92% | -9.33% |
Free Cash Flow | -1,460 | -15,692 | -6,322 | -11,649 | 8,496 |
Free Cash Flow Per Share | -53.94 | -582.38 | -232.98 | -428.12 | 308.70 |
Dividend Per Share | - | - | - | 400.000 | 500.000 |
Dividend Growth | - | - | - | -20.00% | - |
Gross Margin | 59.66% | 58.97% | 54.92% | 52.49% | 55.22% |
Operating Margin | 3.91% | 1.35% | -15.34% | 4.55% | 8.87% |
Profit Margin | 4.35% | 2.82% | -12.73% | 6.66% | 7.13% |
Free Cash Flow Margin | -0.74% | -8.09% | -3.89% | -6.38% | 4.78% |
EBITDA | 11,344 | 8,044 | -19,106 | 15,016 | 22,770 |
EBITDA Margin | 5.78% | 4.15% | -11.74% | 8.22% | 12.82% |
D&A For EBITDA | 3,678 | 5,420 | 5,849 | 6,704 | 7,011 |
EBIT | 7,666 | 2,624 | -24,955 | 8,312 | 15,758 |
EBIT Margin | 3.91% | 1.35% | -15.34% | 4.55% | 8.87% |
Effective Tax Rate | 7.37% | - | - | 32.49% | 31.50% |
Advertising Expenses | 2,952 | 5,857 | 5,248 | 10,315 | 9,603 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.